Observational Study of Sifrol® in Patients With Primary Restless Legs Syndrome (RLS)

Sifrol® (Pramipexole) Impact on RLS: A 12-weeks Observational Study in Patients With Primary RLS

Study to evaluate treatment effect of pramipexole on RLS severity as measured by IRLS, CGI-I and RLS-6 and to evaluate the time needed to reach maintenance dose of Pramipexole (PPX)

Inclusion Criteria:

• Patients suffering from primary RLS who are planned to be initiated on treatment with pramipexole as part of the routine care could be included into the study
• Patients not pre-treated with any dopaminergic agent (de novo patients) or patients pretreated with dopaminergic medication
• Male or female patients of any age

Exclusion Criteria:

• Treating physicians are asked to consider the regulations described in the Summary of Product Characteristics (SPC) for the treatment with pramipexole